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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a 
novel betacoronavirus that has caused more than 95,000 cases and over 
3,000 deaths worldwide as of early March 2020.1 SARS-CoV-2 is spreading 
around the world.2 However, the true denominator of cases remains unclear. 
Importantly, we know little about risk factors for severe disease or death 
from the current coronavirus disease (COVID-19) in immunocompromised 
patients. A recent nationwide analysis from China identified 18 patients 
afflicted with cancer who were infected by SARS-CoV-2.3 Of these patients, 
two had unknown treatment status and, of the remaining 16, four had 
received chemotherapy or surgery within a month of the infection, and the 
other four were cancer survivors. Interestingly, five (28%) of the 18 were 
lung cancer patients. When compared to patients without cancer (n=1572),  
these patients with cancer (n = 18)were significantly more likely to be 
admitted to the intensive care unit, requiring invasive ventilation, or to die 
(39% vs. 8%, respectively p = 0.0003).3 Those patients tended to have worse
respiratory disease and higher risk of death, suggesting that cancer patients 
infected with SARS-CoV-2 might have worse outcomes.
Cancer patients on active treatments with cytotoxic chemotherapies or
early after hematopoietic stem cell transplantation often suffer from 
myelosuppression leading to defects in their adaptive as well as innate 
immune system.4 In this brief communication, we aim to discuss possible risk
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factors that may lead to worse outcomes in cancer patients and possible 
therapies, by reviewing available data on recent SARS-CoV-2 infections, as 
well as the severe acute respiratory syndrome coronavirus (SARS-CoV-1) and
Middle East respiratory syndrome (MERS)-CoV outbreaks.
SARS-CoV-2 genome’s sequence is 82% similar to severe acute 
respiratory syndrome coronavirus (SARS-CoV-1)5, which caused an epidemic 
in 2002-2003 and similar to MERS that caused the 2012 epidemic in some 
Middle Eastern countries.6,7 Coronaviruses are single-stranded enveloped 
RNA viruses and contain 4 main structures: a spike protein (S), a membrane 
protein (M), an envelope protein (E), and a nucleocapsid (N). These 
structures allow for membrane fusion with S, entry into the cell with M, and 
viral packaging with E and N proteins.8 The virus infects the epithelial cells, 
and able to enter innate immune cells such macrophages and dendritic cell, 
leading to the production of large amount of pro-inflammatory cytokines and 
chemokines.9
Neutralizing antibodies against SARS-CoV-1 found in patients and 
animals infected with SARS-CoV block viral entry by binding to the S 
glycoprotein.10 Besides the humoral response, the role of T cells in viral 
infections is believed to be just as important. Whilst neutralizing antibodies 
can prevent viral entry, the body also requires SARS-CoV specific CD4+ T 
helper cells for the development of these specific antibodies. Similarly, 
CD8+ cytotoxic T cells are important for the recognition and killing of infected
cells, particularly in the lungs of infected individuals. The epitopes of the S 
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and N proteins become highly immunogenic and produce robust CD8+ T cell-
mediated responses. These responses have been shown to also be durable 
and produce memory responses.11 Therapies that hinder humoral immunity 
by eliminating B cell function, such as rituximab for various lymphomas, as 
well as T cell function as in cytotoxic chemotherapies, may put these 
patients at significantly higher risk of deleterious effects from COVID-19 
infection. Previous data from MERS and SARS infection show that early CD8+
T cell responses are directly related to infection severity.12,13 Additionally, in 
patients who are elderly and with existing lung disease, there is a higher risk 
of infection.14 This higher risk could be extrapolated to our patients with 
cancer that should also be considered at high risk for worse outcomes from 
SARS-CoV-2, and includes especially lung cancer patients as described in a 
report from China for patients with COVID 19 and cancer3 or patients with 
metastases to the lungs, those that have radiation-induced lung injury or 
interstitial lung disease or pneumonitis from checkpoint inhibitors.  In 
addition, patients with hematologic malignancies and/or undergoing T-cell 
depleting therapies or on immunosuppression post-allogeneic hematopoietic 
cell transplantation for example may be at significant risk of acquiring the 
infection as well as progressing to a severe infection. With this in mind, it is 
reasonable to suggest that new therapies such as viral protease inhibitors 
and other strategies such as vaccination or monoclonal antibodies be 
investigated in the most susceptible patients at risk for fatal outcomes. 
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There are ongoing trials with remdesivir, previously developed for the 
Ebola epidemic as well as trials to repurpose HIV inhibitors, 
lopinavir/ritonavir, and other viral protease inhibitors.15 There is a paucity of 
data relating to tyrosine kinase inhibitors (TKIs) and their activity on SARS, 
MERS, and COVID-19; however, there is evidence that certain TKIs may be 
active against these viruses, but this type of therapy would be experimental 
at best.16-18 However, some TKIs may cause myelosuppression, albeit in a 
minority of patients, and this side effect could obviate any potential benefit. 
There are yet no published data on TKIs for COVID-19 nor is there data about
the role or impact that immune checkpoint blockade may play in 
susceptibility to contracting the virus, severity of the disease, or potential 
treatment. There are more than 80 clinical trials pending or ongoing testing 
a variety of agents in hopes to find a potent viral inhibitor with minimal 
adverse profile.19 Whether there is a role for immunotherapy, where the 
immune response is stimulated and infected cells may be more vulnerable, 
needs to be determined in future trials for patients with severe COVID-19 
infections.20 
We propose several major strategies for patients with cancer in this 
COVID-19 epidemic, and in future epidemics with emergent pathogens that 
may be highly transmissible and/or causing severe infections. First, personal 
protection should be emphasized for patients with cancer on active therapy 
or cancer survivors. Second, more intensive surveillance or treatment should
be considered when patients with cancer are infected with SARS-CoV-2, 
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especially in older patients or those with other comorbidities.3 Extra vigilance 
to protect patients with cancer  is reasonable.
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